Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Insights - The company's performance met expectations, with total revenue for 2024 reaching HKD 4.441 billion, a year-on-year increase of 19%, and net profit attributable to shareholders at HKD 2.106 billion, up 11% year-on-year [6] - The fleet structure is continuously optimized, with a total fleet size of 138 vessels as of the end of 2024, and an average age of 4.03 years. The company is focusing on high-value and younger vessels, enhancing its market competitiveness [6] - Cost control measures have been strengthened, with the average cost of interest-bearing liabilities reduced to 3.5%, down 18 basis points year-on-year, which is significantly lower than the industry average [6] - The company maintains a high dividend payout ratio, with a dividend per share of HKD 0.134 for the year, resulting in a payout ratio of 39%. The expected dividend yield for 2025 is approximately 9% [6] - The company has been re-included in the Hong Kong Stock Connect, which is expected to enhance liquidity and accelerate value recovery [6] - The profit forecasts for 2025-2027 have been slightly adjusted upwards, with net profits projected at HKD 2.338 billion, HKD 2.550 billion, and HKD 2.790 billion respectively [6] Financial Data and Profit Forecast - Total revenue (in million HKD) for the years 2023 to 2027 is projected as follows: 3,745 (2023), 4,441 (2024), 4,332 (2025E), 4,526 (2026E), and 4,661 (2027E) [2][7] - Net profit attributable to shareholders (in million HKD) is forecasted as: 1,902 (2023), 2,106 (2024), 2,338 (2025E), 2,550 (2026E), and 2,790 (2027E) [2][7] - Earnings per share (in HKD) are expected to be: 0.31 (2023), 0.34 (2024), 0.35 (2025E), 0.38 (2026E), and 0.42 (2027E) [2][7] - Return on equity (ROE) is projected to remain stable around 15% for the forecast period [6]

2024 年公司营收同比+4.2%，归母净利润同比-17.7%。2024 年公司实现 营收 34.4 亿元（+4.2%，同比变化，下同），其中商业代建收入 27.5 亿元 （+17.3%），政府代建收入 6.26 亿元（-20.6%）。公司 2024 年实现归母净利 润 8.01 亿元（-17.7%）。主要由于代建行业竞争加剧，代建费率下行，期内公 司商业代建毛利率为 51.2%（-1.1pct），政府代建毛利率为 40.1%（-5.1pct）， 拖累公司整体毛利率至 49.6%（-2.6pct）。同时，因房地产行业持续调整，公 司委托方销售受到影响，进而影响项目建设速度与公司账款回收的情况，公司 期末合同资产为 13.4 亿元（+51.0%），贸易及其他应收款为 11.2 亿元 （+35.9%）。 公司新拓金额、单价出现一定下滑，区域结构、委托方结构有所优化。2024 年公司新拓代建合约面积 3650 万方（+3.4%），新拓代建项目代建费 93.2 亿 元（-10.1%），新拓单价 255 元/平方米（-13.1%）。虽然新拓金额、单价下 滑，但公司 2024 年新签市占率 22.1%，继续保持代建市场龙 ...

Investment Rating - The investment rating for the company is "Accumulate" (maintained) [5] Core Views - The company is steadily advancing its global layout and emphasizes its IP channel's capacity to capture demand [5] - The company achieved significant revenue growth in 2024, with a total revenue of 16.994 billion RMB, representing a year-on-year increase of 22.8% [7] - The company completed its annual store opening target, with a total of 7,780 stores by the end of 2024, including 6,504 Miniso stores [7] - The overseas store expansion is notable, with 631 new stores opened abroad, accounting for 58% of total new openings [7] - The company's gross margin reached a historical high of 44.9% in 2024, up 3.7 percentage points year-on-year, driven by an increase in overseas direct sales [7] Financial Performance Summary - Revenue projections for the company are as follows: - 2023: 11,473.21 million RMB - 2024: 16,994.03 million RMB - 2025E: 20,851.52 million RMB - 2026E: 24,818.06 million RMB - 2027E: 29,259.03 million RMB - The expected year-on-year growth rates for revenue are 13.76% in 2023, 48.12% in 2024, and 22.70% in 2025 [6] - The adjusted net profit for 2025 is projected to be 3,123.30 million RMB, with a year-on-year growth rate of 19.3% [6] - The earnings per share (EPS) are expected to increase from 1.42 RMB in 2023 to 2.50 RMB in 2025 [6] Store Expansion and Product Strategy - The company has successfully launched new products under the WAKUKU brand, with a recent release selling out within two hours, indicating strong consumer interest [7] - The TOPTOY brand has also seen rapid overseas expansion, achieving a revenue of 984 million RMB in 2024, a year-on-year increase of 44.7% [7] - The company is focusing on adjusting its revenue structure and IP product mix to enhance gross margin performance [7]

Investment Rating - The report maintains a "Strong Buy" investment rating for TCL Electronics [4]. Core Views - The company has implemented an equity incentive plan that exceeds expectations, granting a total of 91.5 million shares to 860 incentive recipients, with performance targets set for adjusted net profit growth from 2024 to 2027 [1][8]. - TCL's global expansion strategy is resilient against tariff challenges, with significant production capacities in Mexico and Vietnam, allowing the company to mitigate cost risks effectively [8]. - The penetration rate of MiniLED technology is rapidly increasing, driven by government subsidies, with expectations for substantial growth in sales and market share in the coming years [8]. Financial Data and Valuation - Total revenue projections for TCL Electronics are as follows: - 2023: 79,111 million HKD - 2024: 99,322 million HKD (26% YoY growth) - 2025E: 116,149 million HKD (17% YoY growth) - 2026E: 137,888 million HKD (19% YoY growth) - 2027E: 158,475 million HKD (15% YoY growth) [3][10]. - The forecasted net profit for 2025-2027 is adjusted to 2.307 billion HKD, 2.798 billion HKD, and 3.202 billion HKD, representing YoY growth rates of 31%, 21%, and 14% respectively [8]. - The company's PE ratio is projected to decrease from 26.6 in 2023 to 6.2 in 2027, indicating an improving valuation over time [11]. Stock Performance - TCL Electronics has shown strong stock performance with absolute returns of 13% over 1 month, 57% over 6 months, and 98% over 12 months [6].

Investment Rating - The report maintains an "Outperform" rating for the company [4][7]. Core Views - The company is a leading player in the domestic fluorosilicon industry, benefiting significantly from the rising demand for refrigerants [1][2]. - The company has a comprehensive fluoropolymer industry chain and is continuously expanding its high-end product offerings [3]. - The organic silicon supply landscape is improving, with sustained demand growth expected [3]. Summary by Sections Company Overview - Established in 1987, the company has become a leader in China's fluorosilicon industry, with major revenue sources from refrigerants, fluoropolymers, and organic silicon materials [1][16]. - The company has a total refrigerant production quota of 129,900 tons for 2025, leading the domestic market [1][2]. Refrigerant Business - The company is the largest producer of R22 and R32 in China, holding significant production capacities and quotas [2]. - The average price of the company's refrigerant products is projected to increase, leading to substantial profit growth [2]. Fluoropolymer Business - The company has a strong position in the fluoropolymer market, with a focus on high-end products driven by emerging demands [3]. - The company is expected to benefit from the recovery of profit margins in the organic silicon industry [3]. Financial Forecast and Valuation - The company is projected to achieve net profits of 811 million, 2.177 billion, and 2.953 billion yuan for 2024, 2025, and 2026 respectively, with significant growth rates [4][8]. - The reasonable valuation range for the company's stock is estimated to be between 9.51 and 10.86 HKD [4].

Investment Rating - The investment rating for the company is "Accumulate" [6] Core Views - The company reported a revenue of 762 million yuan for 2024, representing a year-on-year increase of 14.4%, and a net profit of 254 million yuan, which is a significant year-on-year growth of 74.6%. The high profit growth is driven by breakthroughs in overseas business, increased market share of key domestic products, and optimized expense ratios [1][5] - The company is expected to maintain a high net profit margin in 2025, despite potential short-term pressure on domestic revenue due to centralized procurement impacts [1][4] Summary by Sections Growth Potential - Domestic revenue may face short-term pressure due to centralized procurement impacts on hemorrhagic products, which saw a revenue of 402 million yuan in 2024, down 5.5% year-on-year. However, ischemic/narrowing products are expected to continue growing, with revenue from atherosclerotic narrowing products reaching 268 million yuan, up 74.6% year-on-year [2] - The acute ischemic product segment is projected to maintain high growth, with revenue of 47 million yuan in 2024, up 82.0% year-on-year, driven by new product launches [2] International Expansion - The company achieved overseas revenue of 75 million yuan in 2024, a remarkable increase of 137.6% year-on-year, marking its first year of profitability in international markets. The company has commercialized eight products across 30 countries and regions [3] Profitability - The gross profit margin is expected to remain around 70%. In 2024, the gross profit margin was 73.0%, a decrease of 3.9 percentage points year-on-year, primarily due to the decline in revenue from hemorrhagic products and price reductions from centralized procurement [4] - The net profit margin reached 32.7% in 2024, a significant increase of 12.5 percentage points year-on-year, and is expected to maintain around 30% in 2025 due to ongoing cost reduction and efficiency improvement strategies [4] Financial Forecast and Investment Recommendations - Revenue projections for 2025-2027 are 828 million yuan, 1.002 billion yuan, and 1.197 billion yuan, representing year-on-year growth rates of 8.72%, 20.95%, and 19.49% respectively. Net profit forecasts are 256 million yuan, 321 million yuan, and 384 million yuan, with corresponding year-on-year growth rates of 0.67%, 25.48%, and 19.74% [5][11]

汇通达网络(09878) 报告日期：2025 年 04 月 11 日 业务结构优化，发展新阶段重回快车道 ——汇通达网络年报点评报告 投资要点 证券研究报告 | 公司点评 | IT 服务Ⅱ 投资评级: 买入(维持) 2024 年服务业务板块业务结构： 门店 SaaS+订阅 5亿（-9%），商家解决方案 1亿 （+8%）。截至 24 年底，公司注册会员零售门店突破 24.9 万家，同增 5%；活跃 会员零售门店达 9.5万家，同增 5%；订阅 SaaS+用户总数近 10.8 万家，其中付费 SaaS+用户超 3.8 万家。 渠道端线上线下两手抓，2024 年新渠道销售额达 36 亿。截至 2024 年底，公司线 下渠道已覆盖全国 21 个省、2.5 万乡镇、24.8 万家会员店。此外进一步布局线 上、社群和海外渠道，试点开展社交电商和内容电商业务，上线社交电商"芸豆 派"商城；私域与社群渠道，推进政采企采，与积分礼品等平台达成战略合作。 此外亦积极试点跨境出海业务，销售阿尔蒂沙空调等产品。 ❑ 迎合时代浪潮，接入 DeepSeek 大模型 公司旗下"千橙云 SaaS+"平台已全面接入 DeepSeek，通过 A ...

Investment Rating - The investment rating for the company is maintained as "Buy" [2][6] Core Views - The company is expected to see a revenue acceleration in Q1 2025, with a projected revenue of 46.6 billion RMB and an adjusted net profit of 700 million RMB [6] - The focus of the company is shifting towards revenue growth and investment, with expectations of expansion in express delivery volume, integrated supply chain customer numbers, and overseas layout [6] - The company is anticipated to achieve a net profit margin of 4.3% in 2024, indicating a strong improvement in profitability [6] - The profit forecast has been adjusted downwards, with expected adjusted net profits for 2025-2027 being 83.07 billion, 91.66 billion, and 105.13 billion RMB respectively, reflecting a growth of 4.93%, 10.34%, and 14.70% [6][7] Financial Data and Profit Forecast - Revenue projections for the company are as follows: - 2023: 166,625 million RMB - 2024: 182,838 million RMB - 2025E: 204,215 million RMB - 2026E: 225,948 million RMB - 2027E: 247,880 million RMB - The adjusted net profit forecasts are: - 2023: 2,761 million RMB - 2024: 7,917 million RMB - 2025E: 8,307 million RMB - 2026E: 9,166 million RMB - 2027E: 10,513 million RMB - The earnings per share (EPS) are projected to be: - 2023: 0.44 RMB - 2024: 1.25 RMB - 2025E: 1.31 RMB - 2026E: 1.45 RMB - 2027E: 1.66 RMB - The price-to-earnings (PE) ratio is expected to decrease from 24 in 2023 to 6 in 2027 [3][7]

Investment Rating - The investment rating for the company is "Buy" and is maintained [6]. Core Insights - In 2024, the company achieved revenue of 3.885 billion, representing a year-on-year growth of 34.6%. The net profit attributable to shareholders was 881 million, up 33%, while the adjusted net profit reached 924 million, growing by 39.2% [2][4]. - The growth was driven by the cosmetics segment, with revenue from color cosmetics and skincare reaching 2.3 billion and 1.43 billion respectively, marking increases of 42% and 23% [7]. - The company has seen a significant increase in membership and repurchase rates, with membership growing from 10.3 million to 15.1 million and online and offline repurchase rates reaching 27.5% and 34.9%, respectively [7]. Summary by Sections Financial Performance - The company reported a total revenue of 3.885 billion in 2024, a 34.6% increase year-on-year. The net profit attributable to shareholders was 881 million, reflecting a 33% growth, while the adjusted net profit was 924 million, up 39.2% [2][4]. - The revenue breakdown shows that color cosmetics generated 2.3 billion, growing by 42%, and skincare products brought in 1.43 billion, with a 23% increase [7]. Market Dynamics - The company experienced strong growth in both online and offline channels, with online revenue increasing by 51% to 1.78 billion and offline revenue growing by 22% to 1.95 billion [7]. - The second half of 2024 continued to show robust performance, with total revenue of 1.91 billion, a 29% year-on-year increase, and color cosmetics growing by 41% [7]. Brand Development - The company is expanding its brand presence with a focus on multiple product categories, including color cosmetics, skincare, and fragrances. The growth strategy is supported by a strong pipeline of quality mid-tier products and enhanced online marketing efforts [7]. - The brand's membership and repurchase rates indicate a healthy growth trajectory, with significant increases in both metrics, showcasing the brand's growing customer loyalty [7].

证券研究报告 | 2025年04月11日 远大医药（00512.HK） 优于大市 2024 年归母净利同比增长 31%，核药龙头杨帆启航 收入同比增长 10.6%，归母净利润同比增长 31.3%。2024 年公司实现收入 116.45 亿港币，同比增长 10.6%，扣除汇率变动影响同比增长约 12.8%；实 现归母溢利 24.68 亿港币，同比增长 31.3%；若扣除对 Telix 投资的公允价 值变动收益（7.08 亿港币），正常化归母溢利约 17.61 亿港币，同比增长约 2.5%，进一步扣除汇率变动的影响后同比增长约 4.6%，在较大的外部环境压 力下保持业绩的良好增长。 五官科和呼吸类产品表现亮眼，核药抗肿瘤板块持续高速放量。扣除汇率变 动影响，2024 年制药科技板块实现收入 73.18 亿港币，同比增长 9.6%，其 中呼吸及危重症业务收入 17.09 亿港币，同比增长约 26.9%，主要因为核心 产品切诺的临床需求持续增长以及新产品恩卓润、恩明润和布地奈德鼻喷雾 剂的快速放量；五官科业务收入 27.04 亿港币，同比增长 19.3%，主要是新 品销售带来增长；心脑血管急救业务收入 21.76 亿 ...